Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 S.W. Sam Jackson, Portland, OR, 97239, USA.
Curr Treat Options Oncol. 2021 Sep 15;22(11):97. doi: 10.1007/s11864-021-00896-3.
Biliary malignancies, although rare, can be some of the most challenging to manage surgically. Intrahepatic cholangiocarcinomas are resectable if there is no evidence of metastatic disease. These tumors are managed with anatomic resection and portal lymphadenectomy when centrally located or multiple in a single lobe. Non-anatomic resection can be performed for solitary peripheral tumors with minimally invasive techniques. It is not our practice to routinely employ neoadjuvant chemotherapy prior to resection of these tumors. Hepatic arterial infusion chemotherapy is utilized at our institution in highly selected patients in the context of an ongoing clinical trial for unresectable tumors. Hilar cholangiocarcinomas, when resectable (i.e., ipsilateral arterial involvement or lack of vascular involvement), are managed with right or left (extended) hepatectomy, caudate resection, and portal lymphadenectomy. Distal cholangiocarcinomas are managed with pancreaticoduodenectomy. Neoadjuvant chemotherapy is not routinely used in our treatment algorithm of extrahepatic cholangiocarcinomas. Nodal involvement and positive margin (R1) resection necessitates adjuvant chemotherapy. Finally, gallbladder carcinoma is managed with radical cholecystectomy, anatomic segment IVb/V resection, and portal lymphadenectomy. Adjuvant chemotherapy is employed routinely amongst patients with T2 or higher tumors and those with positive lymph nodes.
胆道恶性肿瘤虽然罕见,但在手术治疗方面可能极具挑战性。如果没有转移性疾病的证据,肝内胆管癌是可切除的。这些肿瘤位于中央或单个叶内多发时,采用解剖性切除术和门静脉淋巴结清扫术治疗。对于单发的外周肿瘤,可以采用微创技术进行非解剖性切除术。我们的实践中不常规在切除这些肿瘤之前使用新辅助化疗。在我们的机构中,对于无法切除的肿瘤,在一项正在进行的临床试验背景下,将肝动脉灌注化疗用于高度选择的患者。可切除的肝门部胆管癌(即同侧动脉受累或无血管受累)采用右或左(扩大)肝切除术、尾状叶切除术和门静脉淋巴结清扫术治疗。远端胆管癌采用胰十二指肠切除术治疗。我们的治疗方案中不常规使用新辅助化疗来治疗肝外胆管癌。淋巴结受累和阳性切缘(R1)切除需要辅助化疗。最后,胆囊癌采用根治性胆囊切除术、解剖性 IVb/V 段切除术和门静脉淋巴结清扫术治疗。对于 T2 或更高肿瘤和淋巴结阳性的患者,常规采用辅助化疗。